Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy

Cyclophilin and NS5A Inhibitors, but Not Other Anti-Hepatitis C Virus (HCV) Agents, Preclude HCV-Mediated Formation of Double-Membrane-Vesicle Viral Factories

(2015) Udayan Chatterji et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Mark Sulkowski et al.   LANCET

Hepatitis C

(2015) Daniel P Webster et al.   LANCET

Serine Phosphorylation of the Hepatitis C Virus NS5A Protein Controls the Establishment of Replication Complexes

(2015) Douglas Ross-Thriepland et al.   JOURNAL OF VIROLOGY

Efficacy of daclatasvir in hepatitis C virus

(2014) Namiki Izumi   Expert Review of Anti-Infective Therapy

Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors

(2014) David R. McGivern et al.   GASTROENTEROLOGY

Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes

(2014) Masao Honda et al.   HEPATOLOGY

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

(2014) Mika Miura et al.   HEPATOLOGY RESEARCH

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1

(2014) K. Kosaka et al.   JOURNAL OF VIRAL HEPATITIS

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

(2014) Michael Manns et al.   LANCET

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

(2014) Peter Ferenci et al.   NEW ENGLAND JOURNAL OF MEDICINE

The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors

(2014) Sebastian M. Lambert et al.   PROTEIN SCIENCE

Hepatitis C virus NS5A inhibitors and drug resistance mutations

(2014) Shingo Nakamoto   WORLD JOURNAL OF GASTROENTEROLOGY

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

(2014) David B. Ascher et al.   Scientific Reports

Antiviral therapy for chronic hepatitis C in 2014

(2014) Manogna Nookathota et al.   Expert Review of Clinical Pharmacology

Hepatitis C virus impairs TLR3 signaling and inhibits IFN-λ 1 expression in human hepatoma cell line

(2013) Yizhong Wang et al.   Innate Immunity

Correlation between NS5A Dimerization and Hepatitis C Virus Replication

(2012) Precious J. Lim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

(2011) Jean-Michel Pawlotsky   HEPATOLOGY

Hepatitis C Virus Proteins Inhibit C3 Complement Production

(2011) B. Mazumdar et al.   JOURNAL OF VIROLOGY

Hepatitis C Virus Nonstructural Protein 5A: Biochemical Characterization of a Novel Structural Class of RNA-Binding Proteins

(2010) J. Hwang et al.   JOURNAL OF VIROLOGY

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

The Hepatitis C Virus Non-structural NS5A Protein Impairs Both the Innate and Adaptive Hepatic Immune Responsein Vivo

(2009) Malte Kriegs et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

(2009) R. A. Love et al.   JOURNAL OF VIROLOGY

Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells

(2008) P Colombatto et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

(2008) Nicole Appel et al.   PLoS Pathogens